A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

International Clinical Psychopharmacology

Volumn 19, Issue 2, 2004, Pages 63-69

  Mortimer, Ann ^a   Martin, Stephen ^b   Lôo, Henri ^c   Peuskens, Joseph ^d  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF SUNDERLAND   (United Kingdom)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Amisulpride; Efficacy; Olanzapine; Randomized clinical trial; Schizophrenia

Indexed keywords

AMINOTRANSFERASE; AMISULPRIDE; OLANZAPINE;

ADULT; AGED; AMENORRHEA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEBEPHRENIA; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; SOCIAL STATUS; SOMNOLENCE; SYMPTOMATOLOGY; WEIGHT GAIN;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME;

EID: 1542299050     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200403000-00002     Document Type: Article

References (42)

1. Adams CE, Coutinho E, Duggan L, Gilbody S, Leucht S, Wahlbeck K (2003). Cochrane Schizophrenia Group. Cochrane Dtabase Syst Rev 4:CDD51334.
2. Allison DB, Casey DE (2001). Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62 (suppl 7):22-31.
3. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC, USA: American Psychiatric Association.
4. Barnes TRE (1984). A rating scale for akathisia. Br J Psychiatry 154:672-673.
5. Beasley CM Jr, Tollefson GD, Tran PV (1997a). Safety of olanzapine. J Clin Psychiatry 58 (suppl 10):13-17.
6. Beasley CM, Tollefson GD, Tran PV (1997b). Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 58 (suppl 10):7-12.
7. Bell M, Milstein R, Beam-Gould J, Lysaker P, Cicchettti D (1992). The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability and predictive validity. J Nerv Ment Dis 180:723-728.
8. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, et al. (1997). In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 58 (suppl 10):28-36.
9. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158:518-526.
10. Conley RR, Mahmoud R (2001). A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158:765-774.
11. Coulouvrat C, Dondey-Nouvel L (1999). Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 14:209-218.
12. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564.
13. Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A (2000). Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 18:567-579.
14. Geddes J, Freemantle N, Harrison P, Bebbington P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 321:1371-1376.
15. Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, et al. (2003). Olanzapine versus risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 61:303-314.
16. Heinrichs DW, Hanlon TE, Carpenter WT (1984). The quality of life scale: an instrument for rating the schizophrenic deficit symptoms. Schizophr Bull 10:388-398.
17. Henderson DC (2002). Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16: 77-89.
18. Ho BC, Miller D, Nopoulos P, Andreasen NC (1999). A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 60:658-663.
19. Kay SR, Fiszbzin A, Opler LA (1987). The Positive and Negative Syndrome Scale for schizophrenia. Schizophr Bull 13:261-276.
20. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. (2002a). An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59:1021-1026.
21. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. (2002b). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 325:243-248.
22. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51-68.
23. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002). Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180-190.
24. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003). New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581-1589.
25. Martin S, Löo H, Peuskens J, Thirumalai S, Giudicelli A, Fleurot O, et al. (2002). A double-blind randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Curr Med Res Opin 18:355-362.
26. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-329.
27. National Institute for Clinical Excellence (2002). Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal no. 43. London, UK: NICE.
28. National Institute of Mental Health (1976a) CGI, Clinical Global Impression. In: Guy W (editor): ECDEU Assessment Manual of Psychopharmacology Review. Rockville, MD, USA: NIMH, pp. 217-222.
29. National Institute of Mental Health (1976b) CGI, Abnormal involuntary Movement Scale. In: Guy W (editor): ECDEU Assessment Manual of Psychopharmacology Review. Rockville, MD, USA: NIMH, pp. 534-537.
30. Overall JE, Gorham DR (1962). The Brief Psychiatric Rating Scale. Psychol Report 10:799-812.
31. Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W, et al. (1999). Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 88:107-117.
32. Peuskens J, Möller HJ, Peuch A (2002). Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacology 12:305-310.
33. Purdon SE (1999). Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 35 (suppl):S51-S60.
34. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet Q, et al. (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/ D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97.
35. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y (2002). Amisulpride versus risperidone in chronic schizophrenia: results of a 6-month, double-blind study. Neuropsychopharmacology 27:1071-1081.
36. Simpson G, Angus JA (1970). A rating scale for extrapyramidal symptoms. Acta Psychiatr Scand 45 (suppl 42): 11-19.
37. Storosum JG, Elferink AJA, van Zweiten BJ, van Strik R, Hoogendijk WJG, Broekmans AW (2002). Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull 28:193-201.
38. Taylor DM (2002). Antipsychotics and QT prolongation. Acta Psychiatr Scand 107:85-95.
39. 2C serotonin receptors. Nature 374:542-546.
40. Tollefson GD, Sanger TM, Lu Y, Thieme ME (1998). Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55:250-258.
41. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, et al. (1997). Double-blind comparison of olanzapine vs. risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407-418.
42. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159:255-262.